KR20230150834A - Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열 - Google Patents

Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열 Download PDF

Info

Publication number
KR20230150834A
KR20230150834A KR1020237032290A KR20237032290A KR20230150834A KR 20230150834 A KR20230150834 A KR 20230150834A KR 1020237032290 A KR1020237032290 A KR 1020237032290A KR 20237032290 A KR20237032290 A KR 20237032290A KR 20230150834 A KR20230150834 A KR 20230150834A
Authority
KR
South Korea
Prior art keywords
leu
ser
polynucleotide
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237032290A
Other languages
English (en)
Korean (ko)
Inventor
스펜서 박
퀴니 봉
블라이드 새더
병 류
마르크 라주아
Original Assignee
라이엘 이뮤노파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이엘 이뮤노파마, 인크. filed Critical 라이엘 이뮤노파마, 인크.
Publication of KR20230150834A publication Critical patent/KR20230150834A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A61K39/461—
    • A61K39/4631—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020237032290A 2021-02-25 2022-02-24 Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열 Pending KR20230150834A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163153879P 2021-02-25 2021-02-25
US63/153,879 2021-02-25
US202163263231P 2021-10-28 2021-10-28
US63/263,231 2021-10-28
US202263309380P 2022-02-11 2022-02-11
US63/309,380 2022-02-11
PCT/US2022/017733 WO2022182890A1 (en) 2021-02-25 2022-02-24 Codon-optimized nucleotide sequences encoding an ap-1 transcription factor

Publications (1)

Publication Number Publication Date
KR20230150834A true KR20230150834A (ko) 2023-10-31

Family

ID=80999862

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032290A Pending KR20230150834A (ko) 2021-02-25 2022-02-24 Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열

Country Status (7)

Country Link
US (2) US12270032B2 (cg-RX-API-DMAC7.html)
EP (1) EP4298230A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510900A (cg-RX-API-DMAC7.html)
KR (1) KR20230150834A (cg-RX-API-DMAC7.html)
AU (1) AU2022226655A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174248A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022182890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121447A1 (en) 2020-03-20 2023-01-25 Lyell Immunopharma, Inc. Novel recombinant cell surface markers
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JPWO2025089255A1 (cg-RX-API-DMAC7.html) * 2023-10-23 2025-05-01
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025184170A1 (en) * 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
WO2025199252A1 (en) * 2024-03-19 2025-09-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Inducible transcription factor expression for modulating immune cell function

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
CN101851668A (zh) 2009-08-10 2010-10-06 芮屈生物技术(上海)有限公司 一种ap-1基因的原位杂交检测试剂盒及其检测方法和应用
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
GB201515351D0 (en) 2015-08-28 2015-10-14 Cancer Res Technology Antibody
CN106636210B (zh) 2016-10-09 2019-07-19 广州暨南大学医药生物技术研究开发中心 转录因子组合诱导成纤维细胞转分化为类睾丸间质细胞的方法
GB201621889D0 (en) 2016-12-21 2017-02-01 Autolus Ltd Cell
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
EP3723774A4 (en) 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
EP3830114A4 (en) 2018-07-31 2022-08-03 Washington University USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT
MX2021013218A (es) 2019-05-01 2021-12-10 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
AU2021205416B2 (en) * 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor

Also Published As

Publication number Publication date
AU2022226655A9 (en) 2025-01-30
JP2024510900A (ja) 2024-03-12
EP4298230A1 (en) 2024-01-03
US20250297268A1 (en) 2025-09-25
CA3174248A1 (en) 2022-09-01
US20220307039A1 (en) 2022-09-29
US12270032B2 (en) 2025-04-08
WO2022182890A1 (en) 2022-09-01
AU2022226655A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
US12270032B2 (en) Codon-optimized nucleotide sequences encoding an AP-1 transcription factor
TWI728308B (zh) 一種結合bcma的嵌合抗原受體(car)及其應用
US12410248B2 (en) Chimeric antigen receptor and its use
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
JP6846352B2 (ja) キメラ抗原受容体
US20170275366A1 (en) EGFRvIII Specific Chimeric Antigen Receptor For Cancer Immunotherapy
KR20190077562A (ko) TGFβ 신호 컨버터
AU2015367317A1 (en) Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
JP2022512475A (ja) 二量体化剤調節免疫受容体複合体
EP4021464A1 (en) SYNTHETIC CARS TO TREAT IL13Ra2 POSITIVE HUMAN AND CANINE TUMORS
JP2022513460A (ja) 二量体形成剤調節性免疫受容体複合体
KR20250008809A (ko) 다분할 수용체 및 신호전달 복합체
CN110511912A (zh) 免疫细胞的功能调节
KR20250046298A (ko) 자연 살해 세포 기능을 향상시키기 위한 표적 유전자의 유전자 편집
KR20240027676A (ko) Nr4a3-결핍 면역 세포 및 이의 용도
KR20230148837A (ko) Ror1 표적화 키메라 항원 수용체
JP2023539591A (ja) Bcmaキメラ抗原受容体
CN115397864A (zh) 经修饰的ccr多肽和其用途
US20260083846A1 (en) Polynucleotides targeting nr4a3 and uses thereof
CA3257650A1 (en) Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
JP2025522360A (ja) Cd16変異体およびnkg2dを発現する遺伝子操作した細胞ならびにその使用
CN117157407A (zh) 编码ap-1转录因子的密码子优化的核苷酸序列
CN117412985A (zh) 靶向ror1的嵌合抗原受体
WO2026006767A1 (en) Tethered il-9/il-9r and related engineered cells and methods
HK40066141B (en) Genetically engineered cells and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230920

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250224

Comment text: Request for Examination of Application